Bank of America Corporation upgraded shares of Bruker Corporation (NASDAQ:BRKR) from an underperform rating to a neutral rating in a research note issued to investors on Friday, November 3rd, Marketbeat.com reports. They currently have $34.00 price target on the medical research company’s stock.
Other analysts have also issued reports about the stock. Wells Fargo & Company lowered shares of Bruker Corporation from a market perform rating to an underperform rating in a research report on Wednesday, July 12th. Zacks Investment Research upgraded shares of Bruker Corporation from a hold rating to a buy rating and set a $33.00 price target for the company in a research report on Thursday, July 6th. BidaskClub lowered shares of Bruker Corporation from a strong-buy rating to a buy rating in a research report on Friday, July 28th. Barclays PLC restated an equal weight rating and set a $30.00 price target (up from $26.00) on shares of Bruker Corporation in a research report on Monday, July 17th. Finally, Cowen and Company reaffirmed a hold rating and set a $29.00 price objective on shares of Bruker Corporation in a research note on Friday, July 14th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company’s stock. Bruker Corporation has a consensus rating of Hold and an average target price of $29.64.
Shares of Bruker Corporation (NASDAQ:BRKR) opened at $35.22 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. Bruker Corporation has a 1 year low of $21.03 and a 1 year high of $35.42. The stock has a market cap of $5,348.25, a PE ratio of 29.39, a price-to-earnings-growth ratio of 2.91 and a beta of 1.05.
WARNING: “Bruker Corporation (BRKR) Lifted to Neutral at Bank of America Corporation” was reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/bruker-corporation-brkr-rating-increased-to-neutral-at-bank-of-america-corporation/1757290.html.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 22nd. Investors of record on Monday, December 4th will be paid a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, December 1st. Bruker Corporation’s payout ratio is currently 17.02%.
In related news, VP Mark Munch sold 21,061 shares of the stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the completion of the transaction, the vice president now directly owns 60,524 shares of the company’s stock, valued at $1,813,904.28. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 35.20% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Bruker Corporation by 2.9% in the first quarter. Vanguard Group Inc. now owns 9,832,452 shares of the medical research company’s stock worth $229,391,000 after buying an additional 277,111 shares in the last quarter. BlackRock Inc. raised its stake in Bruker Corporation by 3.0% in the second quarter. BlackRock Inc. now owns 4,747,514 shares of the medical research company’s stock worth $136,918,000 after buying an additional 139,792 shares in the last quarter. Boston Partners raised its stake in Bruker Corporation by 3.6% in the second quarter. Boston Partners now owns 2,773,019 shares of the medical research company’s stock worth $79,973,000 after buying an additional 96,791 shares in the last quarter. Victory Capital Management Inc. raised its stake in Bruker Corporation by 6.8% in the second quarter. Victory Capital Management Inc. now owns 1,930,209 shares of the medical research company’s stock worth $55,667,000 after buying an additional 123,322 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Bruker Corporation by 3.9% during the second quarter. Russell Investments Group Ltd. now owns 1,631,538 shares of the medical research company’s stock valued at $47,053,000 after purchasing an additional 60,795 shares in the last quarter. 66.27% of the stock is owned by institutional investors.
About Bruker Corporation
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with our FREE daily email newsletter.